Experience

Entrepreneur First

• United Kingdom
• Venture Capital and Private Equity Principals
• 400 - 500 Employee

• Venture Partner

  • Oct 2022 - Present



Revena

• United Kingdom
• Biotechnology Research
• 1 - 100 Employee

• Co-Founder & Consultant

  • Sep 2019 - Present

  As a consultant with Revena (formerly Revenant Bio), Dr Olof works with high-tech small medium enterprises (SMEs) advising on strategy, fundraising and operational management. As a consultant with Revena (formerly Revenant Bio), Dr Olof works with high-tech small medium enterprises (SMEs) advising on strategy, fundraising and operational management.



Science Creates Ventures

• United Kingdom
• Venture Capital and Private Equity Principals
• 1 - 100 Employee

• Co-Founder & General Partner

  • Sep 2020 - Nov 2021

  Science Creates is a Bristol-based deep tech ecosystem supported and backed by successful entrepreneurs that helps scientists and engineers accelerate their ideas and build disruptive businesses from scientific discoveries. In partnership with the University of Bristol, Science Creates aims to establish Bristol as a global centre for deep tech by providing a combination of specialist incubator facilities, a network of strategic partners and venture capital. The ecosystem aims to provide better healthcare, a cleaner environment, and an improved quality of life for everyone; achieved by supporting scientists to take discoveries off the shelf and into the real world. Show less



Entrepreneur First

• United Kingdom
• Venture Capital and Private Equity Principals
• 400 - 500 Employee

• Entrepreneur In Residence

  • Sep 2019 - Mar 2020

  Entrepreneur First brings together extraordinary people to build startups from scratch in London, Singapore, Berlin, Hong Kong, Paris and Bangalore. EF funds individuals and help build co-founding teams, develop ideas, and accelerate through fundraising from the world's best investors. EF have built over 150 companies, have over 1000 alumni worldwide, and our portfolio has a valuation of over $1.5 billion. EF's major exits to date include Magic Pony, led by Rob Bishop and Zehan Wang, which was acquired by Twitter for a reported $150 million only 18 months after the founders met on the EF programme.* For more information about Entrepreneur First, check out www.joinef.com. Show less



OxSyBio

• • Jan 2019 - Aug 2019

  Dr. Olof stepped into the role of acting CEO during the phased shut down of OxSyBio.

• • Oct 2018 - Jan 2019

  Dr. Olof is the Chief Business Development Officer at OxSyBio. He leads OxSyBio’s business development activities working to build strategic partnerships.



OxSyBio

• • Jan 2017 - Aug 2018

  As the Chief Technical Officer at OxSyBio, Dr. Olof led OxSyBio’s technical activities in the 3D printing of artificial and synthetic tissues for diagnostic and therapeutic uses.Dr. Olof led OxSyBio’s technical activities in the 3D printing of artificial and synthetic tissues for diagnostic and therapeutic uses. He has helped to grow OxSyBio to the current headcount (double digit FTEs), through Seed (£1 m) and Series A funding (£10 m) rounds.

• • Jan 2016 - Jan 2017

  Dr. Olof was the Technical Director at OxSyBio and a Visiting Scientist in Chemical Biology at the University of Oxford. As a Postdoctoral Fellow, within the Bayley Group, he investigated the 3D printing of artificial tissues. This work informed OxSyBio’s efforts in printed cell networks and has led to the submission of 2 patent applications and the raising of £1 m seed funding.



University of Oxford

• United Kingdom
• Research Services
• 700 & Above Employee

• Postdoctoral Fellow

  • Oct 2013 - Jan 2016



University of Bristol

• United Kingdom
• Higher Education
• 700 & Above Employee

• PHD Student

  • 2009 - 2013